Gene methylation in rectal cancer: Predictive marker of response to chemoradiotherapy?

Journal of Cellular Physiology

Volumn 228, Issue 12, 2013, Pages 2343-2349

  Molinari, Chiara ^a   Casadio, Valentina ^a   Foca, Flavia ^a   Zingaretti, Chiara ^b   Giannini, Massimo ^a   Avanzolini, Andrea ^c   Lucci, Enrico ^c   Saragoni, Luca ^c   Passardi, Alessandro ^a   Amadori, Dino ^a   Calistri, Daniele ^a   Zoli, Wainer ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b National Institute of Molecular Genetics   (Italy)

^c MORGAGNI PIERANTONI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; FLUOROURACIL;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER REGRESSION; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; PRIORITY JOURNAL; RECTUM CARCINOMA; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; CHEMORADIOTHERAPY; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENES, TUMOR SUPPRESSOR; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; RECTAL NEOPLASMS; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR MARKERS, BIOLOGICAL;

EID: 84882590994     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24405     Document Type: Article

References (34)

1. Ahuja N, Issa JP. 2000. Aging, methylation, and cancer. Histol Histopathol 15:835-842.
2. Bai AH, Tong JH, To KF, Chan MW, Man EP, Lo KW, Lee JF, Sung JJ, Leung WK. 2004. Promoter hypermethylation of tumor-related genes in the progression of colorectal neoplasia. Int J Cancer 112:846-853.
3. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. 1998. Alterations in DNA methylation: A fundamental aspect of neoplasia. Adv Cancer Res 72:141-196.
4. Berginc G, Bracko M, Glavac D. 2010. MS-MLPA reveals progressive age-dependent promoter methylation of tumor suppressor genes and possible role of IGSF4 gene in colorectal carcinogenesis of microsatellite instable tumors. Cancer Invest 28:94-102.
5. Brabender J, Arbab D, Huan X, Vallböhmer D, Grimminger P, Ling F, Neiss S, Bollschweiler E, Schneider PM, Hölscher AH, Metzger R. 2009. Death-associated protein kinase (DAPK) promoter methylation and response to neoadjuvant radiochemotherapy in esophageal cancer. Ann Surg Oncol 16:1378-1383.
6. Brueckl WM, Grombach J, Wein A, Ruckert S, Porzner M, Dietmaier W, Rümmele P, Croner RS, Boxberger F, Kirchner T, Hohenberger W, Hahn EG, Jung A. 2005. Alterations in the tissue inhibitor of metalloproteinase-3 (TIMP-3) are found frequently in human colorectal tumours displaying either microsatellite stability (MSS) or instability (MSI). Cancer Lett 223:137-142.
7. de Maat MFG, van de Velde CJH, van der Werff MPJ, Putter H, Umetani N, Meershoek Klein-Kranenbarg E, Turner RR, van Krieken JHJM, Bilchik A, Tollenaar RAEM, Hoon DSB. 2008. Quantitative analysis of methylation of genomic loci in early-stage rectal cancer predicts distant recurrence. J Clin Oncol 26:2327-2335.
8. de Maat MFG, van de Velde CJH, Benard A, Putter H, Morreau H, van Krieken JHJM, Meershoek Klein-Kranenbarg E, de Graaf EJ, Tollenaar RAEM, Hoon DSB. 2010. Identification of a quantitative mint locus methylation profile predicting regional recurrence of rectal cancer. Clin Cancer Res 16:2811-2818.
9. Dworak O, Keilholz L, Hoffmann A. 1997. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12:19-23.
10. Ghadimi BM, Grade M, Difilippantonio MJ, Varma S, Simon R, Montagna C, Füzesi L, Langer C, Becker H, Liersch T, Ried T. 2005. Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. J Clin Oncol 23:1826-1838.
11. Goel A, Shin SK. 2008. CpG island methylator phenotype in colorectal cancer: A current perspective. Curr Colorectal Cancer Rep 4:77-83.
12. Hamilton JP, Sato F, Greenwald BD, Suntharalingam M, Krasna MJ, Edelman MJ, Doyle A, Berki AT, Abraham JM, Mori Y, Kan T, Mantzur C, Paun B, Wang S, Ito T, Jin Z, Meltzer SJ. 2006. Promoter methylation and response to chemotherapy and radiation in esophageal cancer. Clin Gastroenterol Hepatol 4:701-708.
13. Hibi K, Kodera Y, Ito K, Akiyama S, Nakao A. 2004. Methylation pattern of CDH13 gene in digestive tract cancers. Br J Cancer 91:1139-1142.
14. Hiraoka S, Kato J, Horii J, Saito S, Harada K, Fujita H, Kuriyama M, Takemoto K, Uraoka T, Yamamoto K. 2010. Methylation status of normal background mucosa is correlated with occurrence and development of neoplasia in the distal colon. Hum Pathol 41:38-47.
15. Hofstetter B, Niemierko A, Forrer C, Benhattar J, Albertini V, Pruschy M, Bosman FT, Catapano CV, Ciernik IF. 2010. Impact of genomic methylation on radiation sensitivity of colorectal carcinoma. Int J Radiat Oncol Biol Phys 76:1512-1519.
16. Iacopetta B. 2002. Are there two sides to colorectal cancer? Int J Cancer 101:403-408.
17. Iacopetta B, Kawakami K, Watanabe T. 2008. Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: Is the CpG island methylator phenotype the 5-fuorouracil-responsive subgroup? J Clin Oncol 13:498-503.
18. Jo P, Jung K, Grade M, Conradi LC, Wolff HA, Kitz J, Becker H, Rüschoff J, Hartmann A, Beissbarth T, Müller-Dornieden A, Ghadimi M, Schneider-Stock R, Gaedcke J. 2012. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer. Surgery 151:564-570.
19. Kim IJ, Lim SB, Kang HC, Chang HJ, Ahn SA, Park HW, Jang SG, Park JH, Kim DY, Jung KH, Choi HS, Jeong SY, Sohn DK, Kim DW, Park JG. 2007. Microarray gene expression profiling for predicting complete response to preoperative chemoradiotherapy in patients with advanced rectal cancer. Dis Colon Rectum 50:1342-1353.
20. Kim MS, Lee J, Sidransky D. 2010. DNA methylation markers in colorectal cancer. Cancer Metastasis Rev 29:181-206.
21. Kuremsky JG, Tepper JE, McLeod HL. 2009. Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 74:673-688.
22. Kurkjian C, Kummar S, Murgo AJ. 2008. DNA methylation: Its role in cancer development and therapy. Curr Probl Cancer 32:187-235.
23. Leong KJ, Wei W, Tannahill LA, Caldwell GM, Jones CE, Morton DG, Matthews GM, Bach SP. 2011. Methylation profiling of rectal cancer identifies novel markers of early-stage disease. Br J Surg 98:724-734.
24. Moelans CB, Verschuur-Maes AHJ, van Diest PJ. 2011. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer. J Pathol 225:222-231.
25. Nygren A, Ameziane N, Duarte H, Vijzelaar R, Waisfisz Q, Hess C, Schouten JP, Errami A. 2005. A methylation-specific MLPA (MS-MLPA): Simultaneous detection of CpG methylation and copy number changes of up to 40 sequences. Nucleic Acids Res 33:e128.
26. Ogino S, Kawasaki T, Kirkner GJ, Loda M, Fuchs CS. 2006. CpG island methylator phenotype-low (CIMP-Low) in colorectal cancer: Possible associations with male sex and KRAS mutations. J Mol Diagn 8:582-588.
27. Samowitz WS, Albertsen H, Herrick J, Levin TR, Sweeney C, Murtaugh MA, Wolff RK, Slattery ML. 2005. Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology 129:837-845.
28. Sasaki S, Kobunai T, Kitayama J, Nagawa H. 2008. DNA methylation and sensitivity to antimetabolites in cancer cell lines. Oncol Rep 19:407-412.
29. Toyooka S, Toyooka KO, Harada K, Miyajima K, Makarla P, Sathyanarayana UG, Yin J, Sato F, Shivapurkar N, Meltzer SJ, Gazdar AF. 2002. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Res 62:3382-3436.
30. Toyota M, Suzuki H. 2010. Epigenetic drivers of genetic alterations. Adv Genet 70:309-323.
31. Toyota M, Suzuki H, Yamashita T, Hirata K, Imai K, Tokino T, Shinomura Y. 2009. Cancer epigenomics: Implications of DNA methylation in personalized cancer therapy. Cancer Sci 100:787-791.
32. Worthley DL, Whitehall VLJ, Buttenshaw RL, Irahara N, Greco SA, Ramsnes I, Mallitt KA, Le Leu RK, Winter J, Hu Y, Ogino S, Young GP, Leggett BA. 2010. DNA methylation within the normal colorectal mucosa is associated with pathway-specific predisposition to cancer. Oncogene 29:1653-1662.
33. Xu XL, Yu J, Zhang HY, Sun MH, Gu J, Du X, Shi DR, Wang P, Yang ZH, Zhu JD. 2004. Methylation profile of the promoter CpG islands of 31 genes that may contribute to colorectal carcinogenesis. World J Gastroenterol 10:3441-3454.
34. Zhou XY, Sun JF, He YH, Zhang HY, Yu J, Guo SC, Cai Y, Hu XC, Zhu JD. 2010. Correlation of the methylation status of CpG islands in the promoter region of 10 genes with the 5-Fu chemosensitivity in 3 breast cancer cell lines. Zhonghua Zhong Liu Za Zhi 32:328-333.